TY - JOUR T1 - Simvastatin was cost effective across a broad range of risk and age groups JF - Evidence Based Medicine JO - Evid Based Med SP - 58 LP - 58 DO - 10.1136/ebm.12.2.58 VL - 12 IS - 2 A2 - , Y1 - 2007/04/01 UR - http://ebm.bmj.com/content/12/2/58.abstract N2 - Heart Protection Study Collaborative Group. Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people. BMJ 2006;333:1145.OpenUrlAbstract/FREE Full Text 
 
 Q Is 40 mg/day of generic simvastatin continued for life cost effective in patients of different ages with differing risks of vascular disease? Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ Cardiology ★★★★★★☆ Internal medicine ★★★★★☆☆ Design: cost effectiveness study using a Markov model developed from a randomised {allocation concealed*}†, blinded {patients, clinicians, data collectors, and outcome assessors}†,* placebo controlled trial with mean 5 year follow up (Heart Protection Study [HPS]). Setting: 69 UK hospitals. Patients: 20 536 patients 40–80 years of age with total cholesterol concentrations ⩾3.5 mmol/l (135 mg/dl) and history of coronary disease, cerebrovascular disease, other occlusive arterial disease, diabetes mellitus, or treated hypertension (in men ⩾65 y). Within the HPS, patients were divided into 5 similar sized groups by estimated 5 year risk of a major vascular event (12%, … ER -